Skip to main content

Sanuwave Announces Revenues and Financial Results for Q1 FY2026

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025. Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2026. Q1 2026 ended March 31, 2026Revenue for the three months ended March 31, 2026, totaled $9.6 million, an increase of 3.1%,...

Continue reading

Total Energy Services Inc. Announces Q1 2026 Results

CALGARY, Alberta, May 12, 2026 (GLOBE NEWSWIRE) — Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three months ended March 31, 2026. Financial Highlights ($000’s except per share data, unaudited)    Three months endedMarch 31      2026     2025   ChangeRevenue   $ 314,896   $ 251,909   25 %Operating income     27,129     26,063   4 %EBITDA(1)     55,158     50,488   9 %Cashflow     54,290     44,934   21 %Net income     24,222     18,952   28 %Attributable to shareholders     24,137     18,966   27 %                 Per Share Data (Diluted)                EBITDA(1)   $ 1.49   $ 1.31   14 %Cashflow   $ 1.46   $ 1.16   26 %                 Attributable to shareholders:                Net income   $ 0.65   $ 0.49   33 %                 Common...

Continue reading

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well-capitalized into H2 2028, beyond key catalysts with over $140 million cash VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2026. “The clinical data reported this quarter further reinforces the potential for EP-104GI to become an important new...

Continue reading

ArrowMark Financial Corp. Announces Monthly Cash Distribution of $0.15 per Share for May 2026

DENVER, May 12, 2026 (GLOBE NEWSWIRE) — ArrowMark Financial Corp. (Nasdaq: BANX) (“ArrowMark Financial” or the “Company”), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a monthly cash distribution of $0.15 per share for May 2026. The total distribution of $0.15 per share will be payable on May 29, 2026, to shareholders of record on May 22, 2026. “We are very pleased to announce the regular monthly distribution of $0.15. We believe these distributions reflect the Fund’s ability to consistently over-earn its declared monthly distribution rate. ArrowMark Financial is committed to providing consistent risk-adjusted returns while maintaining focus on capital preservation and income generation for our shareholders,” said Chairman & CEO...

Continue reading

Allied Announces Voting Results from the 2026 Annual Meeting of Unitholders

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”) (TSX:AP.UN) announced today the results of matters voted on at its annual meeting of the holders (the “Unitholders”) of units and special voting units of Allied (collectively, “Units”) held on May 12, 2026 (the “Meeting”). All of the nominees for election as trustees listed in Allied’s management information circular (the “Circular”) dated March 31, 2026, were elected as trustees of Allied for the ensuing year or until their successors are elected or appointed. Management received proxies in respect of the election of trustees of Allied as follows:  VOTES FOR VOTES WITHHELD  # % # %Matthew Andrade 91,340,837   82.34% 19,591,881   17.66%Mario Barrafato 109,614,857   98.82% 1,312,261   1.18%Kay Brekken 91,436,502   82.43% 19,496,216   17.57%Hazel...

Continue reading

COSCIENS Biopharma Inc. Reports Q1 2026 Results

TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) today reported its financial and operating results for the first quarter ended March 31, 2026. All amounts in this press release are in U.S. dollars. Q1 2026 Financial Highlights$5.0 million in cash and cash equivalents at March 31, 2026. Consolidated net income of $10.8 million or $3.42 net income per common share, as compared with a consolidated net loss of $3.7 million, or $1.16 loss per common share for Q1 2025. The $14.4 million increase in net income is primarily attributable to the $10.9 million of Income from discontinued operations recognized upon the deconsolidation of the Company’s German subsidiaries from the consolidated financial results (as further discussed below). Consolidated net...

Continue reading

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor Clinical readouts expected in the second half of 2026 across all three programs Cash runway expected to fund operations into 2028SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress. BBOT’s portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition...

Continue reading

Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2026 and Declares Quarterly Dividend

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2026 and declared a $1.00 per share dividend payable on July 10, 2026 to all common shareholders of record at close of business on June 19, 2026. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2026 and the accompanying notes, our Management Discussion and Analysis for the three months ended March...

Continue reading

Bel Fuse Inc. Announces Launch of Public Offering of Class B Common Stock

WEST ORANGE, N.J., May 12, 2026 (GLOBE NEWSWIRE) — Bel Fuse Inc. (Nasdaq: BELFA and BELFB) (“Bel” or the “Company”), a leading global manufacturer of electronic components, systems and solutions, today announced the commencement of an underwritten offering of 1,300,000 shares of its Class B common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 195,000 shares of its Class B common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bel currently intends to use the net proceeds from the proposed offering to pay down any outstanding indebtedness...

Continue reading

Evolution Petroleum Reports Fiscal Third Quarter 2026 Results and Declares $0.12 per Share Cash Dividend for the Fiscal Fourth Quarter

HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced its financial and operating results for its fiscal third quarter ended March 31, 2026. Evolution also declared its 16th consecutive $0.12 cash dividend per common share, payable on June 30, 2026, marking its 51st consecutive quarterly cash dividend payment. Financial & Operational Highlights($ in thousands) Q3 2026 Q3 2025 Q2 2026 % Changevs Q3/Q3 % Changevs Q3/Q2 2026 YTD 2025 YTD % Changevs YTD’25Average BOEPD   6,700     6,667     7,380 —   (9)%     7,135     7,033   1%Revenues $ 20,168   $ 22,561   $ 20,679 (11)%   (2)%   $ 62,135   $ 64,732   (4)%Net Income (Loss)(1) $ (8,932)   $ (2,179)   $ 1,065 310%   NM   $ (7,043)   $ (1,939)   263%Adjusted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.